GRAIL (GRAL) Stock Analysis & Winston Score

GRAIL is a biotechnology company focused on early cancer detection. Its main product is Galleri, a blood test that can screen for more than 50 types of cancer using a single draw. The test looks for tiny fragments of cancer DNA floating in the bloodstream — a technology called liquid biopsy. GRAIL sells primarily to healthcare providers and employers in the United States who want to catch cancer earlier, when it is more treatable. GRAIL makes money by charging for each Galleri test performed, targeting both direct-to-consumer and employer-sponsored health programs. The company operates mainly in the US and is still in an early commercial stage, which explains its deeply negative margins — it spends heavily on sales, research, and clinical trials. GRAIL's key advantage is its large proprietary dataset of cancer signals, but the biggest risk is that Galleri has not yet received full FDA approval, which limits insurance coverage and slows widespread adoption.